Glucocorticoid protects rodent hearts from ischemia/reperfusion injury by activating lipocalin-type prostaglandin D synthase-derived PGD2 biosynthesis

Journal of Clinical Investigation

Volumn 119, Issue 6, 2009, Pages 1477-1488

  Tokudome, Satori ^a,b   Sano, Motoaki ^a,c   Shinmura, Ken ^a   Matsuhashi, Tomohiro ^a   Morizane, Shintaro ^a   Moriyama, Hidenori ^a   Tamaki, Kayoko ^a   Hayashida, Kentaro ^a   Nakanishi, Hiroki ^d   Yoshikawa, Noritada ^e   Shimizu, Noriaki ^e   Endo, Jin ^a   Katayama, Takaharu ^a   Murata, Mitsushige ^a   Yuasa, Shinsuke ^a   Kaneda, Ruri ^a   Tomita, Kengo ^a   Eguchi, Naomi ^f   Urade, Yoshihiro ^f   Asano, Koichiro ^a   Utsunomiya, Yasunori ^b   Suzuki, Takeshi ^a   Taguchi, Ryo ^d   Tanaka, Hirotoshi ^e   Fukuda, Keiichi ^a   more..

^a KEIO UNIVERSITY   (Japan)

^b JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

^d Keio University ^*

^e UNIVERSITY OF TOKYO   (Japan)

^f OSAKA BIOSCIENCE INSTITUTE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 2; DEXAMETHASONE; GLUCOCORTICOID RECEPTOR; LIPOCALIN; MIFEPRISTONE; MITOGEN ACTIVATED PROTEIN KINASE 3; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; PHOSPHOLIPASE A2; PROSTAGLANDIN D SYNTHASE; PROSTANOID RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; ENZYME SYNTHESIS; HEART MUSCLE CELL; HEART MUSCLE ISCHEMIA; HEART PROTECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REPERFUSION INJURY;

ANIMALS; ANOXIA; CELLS, CULTURED; CYCLOOXYGENASE 2; ENZYME ACTIVATION; GLUCOCORTICOIDS; HEART; INTRAMOLECULAR OXIDOREDUCTASES; LIPOCALINS; MICE; MICE, KNOCKOUT; MYOCARDIAL REPERFUSION INJURY; OXYGEN; PROSTAGLANDIN D2; RATS; SIGNAL TRANSDUCTION;

EID: 67651005399     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI37413     Document Type: Article

References (43)

1. Sapolsky, R.M., Romero, L.M., and Munck, A.U. 2000. How do glucocorticoids influence stress responses? Integrating permissive, suppressive, stimulatory, and preparative actions. Endocr. Rev. 21:55-89.
2. Libby, P., Maroko, P.R., Bloor, C.M., Sobel, B.E., and Braunwald, E. 1973. Reduction of experimental myocardial infarct size by corticosteroid administration. J. Clin. Invest. 52:599-607.
3. Valen, G., et al. 2000. Glucocorticoid pretreatment protects cardiac function and induces cardiac heat shock protein 72. Am. J. Physiol. Heart Circ. Physiol. 279:H836-H843.
4. Varga, E., et al. 2004. Inhibition of ischemia/reperfusion-induced damage by dexamethasone in isolated working rat hearts: the role of cytochrome c release. Life Sci. 75:2411-2423.
5. Skyschally, A., et al. 2004. Glucocorticoid treatment prevents progressive myocardial dysfunction resulting from experimental coronary microembolization. Circulation. 109:2337-2342.
6. Giugliano, G.R., Giugliano, R.P., Gibson, C.M., and Kuntz, R.E. 2003. Meta-analysis of corticosteroid treatment in acute myocardial infarction. Am. J. Cardiol. 91:1055-1059.
7. Cronstein, B.N., Kimmel, S.C., Levin, R.I., Martiniuk, F., and Weissmann, G. 1992. Corticosteroids are transcriptional regulators of acute inflammation. Trans. Assoc. Am. Physicians. 105:25-35.
8. Radomski, M.W., Palmer, R.M., and Moncada, S. 1990. Glucocorticoids inhibit the expression of an inducible, but not the constitutive, nitric oxide synthase in vascular endothelial cells. Proc. Natl. Acad. Sci. U. S. A. 87:10043-10047.
9. Hafezi-Moghadam, A., et al. 2002. Acute cardiovascular protective effects of corticosteroids are mediated by non-transcriptional activation of endothelial nitric oxide synthase. Nat. Med. 8:473-479.
10. Pascual, G., and Glass, C.K. 2006. Nuclear receptors versus inflammation: mechanisms of transrepression. Trends Endocrinol. Metab. 17:321-327.
11. Hayashi, R., Wada, H., Ito, K., and Adcock, I.M. 2004. Effects of glucocorticoids on gene transcription. Eur. J. Pharmacol. 500:51-62.
12. De Bosscher, K., Vanden Berghe, W., and Haegeman, G. 2003. The interplay between the glucocorticoid receptor and nuclear factor-kappaB or activator protein-1: molecular mechanisms for gene repression. Endocr. Rev. 24:488-522.
13. Walker, B.R. 2007. Glucocorticoids and cardiovascular disease. Eur. J. Endocrinol. 157:545-559.
14. Funder, J.W. 2005. RALES, EPHESUS and redox. J. Steroid Biochem. Mol. Biol. 93:121-125.
15. Yoshikawa, N., et al. 2002. Distinct interaction of cortivazol with the ligand binding domain confers glucocorticoid receptor specificity: cortivazol is a specific ligand for the glucocorticoid receptor. J. Biol. Chem. 277:5529-5540.
16. Yoshikawa, N., et al. 2005. The distinct agonistic properties of the phenylpyrazolosteroid cortivazol reveal interdomain communication within the glucocorticoid receptor. Mol. Endocrinol. 19:1110-1124.
17. Yoshikawa, N., et al. 2009. Ligand-based gene expression profiling reveals novel roles of glucocorticoid receptor in cardiac metabolism. Am. J. Physiol. Endocrinol. Metab. Online publication ahead of print. doi:10.1152/ajpendo.90767.2008.
18. Taguchi, R., Nishijima, M., and Shimizu, T. 2007. Basic analytical systems for lipidomics by mass spectrometry in Japan. Methods Enzymol. 432:185-211.
19. Guo, Y., et al. 2000. Evidence for an essential role of cyclooxygenase-2 as a mediator of the late phase of ischemic preconditioning in mice. Basic Res. Cardiol. 95:479-484.
20. Shibata, R., et al. 2005. Adiponectin protects against myocardial ischemia-reperfusion injury through AMPK- and COX-2-dependent mechanisms. Nat. Med. 11:1096-1103.
21. Zakar, T., Hirst, J.J., Mijovic, J.E., and Olson, D.M. 1995. Glucocorticoids stimulate the expression of prostaglandin endoperoxide H synthase-2 in amnion cells. Endocrinology. 136:1610-1619.
22. Economopoulos, P., Sun, M., Purgina, B., and Gibb, W. 1996. Glucocorticoids stimulate prostaglandin H synthase type-2 (PGHS-2) in the fibroblast cells in human amnion cultures. Mol. Cell. Endocrinol. 117:141-147.
23. Sun, K., et al. 2003. Glucocorticoids induce cytosolic phospholipase A2 and prostaglandin H synthase type 2 but not microsomal prostaglandin E synthase (PGES) and cytosolic PGES expression in cultured primary human amnion cells. J. Clin. Endocrinol. Metab. 88:5564-5571.
24. Abbate, A., et al. 2004. Cyclo-oxygenase-2 (COX-2) expression at the site of recent myocardial infarction: friend or foe? Heart. 90:440-443.
25. Wong, S.C., Fukuchi, M., Melnyk, P., Rodger, I., and Giaid, A. 1998. Induction of cyclooxygenase-2 and activation of nuclear factor-kappaB in myocardium of patients with congestive heart failure. Circulation. 98:100-103.
26. Nito, I., Waspadji, S., Harun, S., and Markum, H.M. 2004. Correlation between cortisol levels and myocardial infarction mortality among intensive coronary care unit patients during first seven days in hospital. Acta Med. Indones. 36:8-14.
27. Eguchi, Y., et al. 1997. Expression of lipocalin-type prostaglandin D synthase (beta-trace) in human heart and its accumulation in the coronary circulation of angina patients. Proc. Natl. Acad. Sci. U. S. A. 94:14689-14694.
28. Gilroy, D.W., et al. 1999. Inducible cyclooxygenase may have anti-inflammatory properties. Nat. Med. 5:698-701.
29. Bushfield, M., McNicol, A., and MacIntyre, D.E. 1985. Inhibition of platelet-activating-factor-induced human platelet activation by prostaglandin D2. Differential sensitivity of platelet transduction processes and functional responses to inhibition by cyclic AMP. Biochem. J. 232:267-271.
30. Braun, M., and Schror, K. 1992. Prostaglandin D2 relaxes bovine coronary arteries by endothelium-dependent nitric oxide-mediated cGMP formation. Circ. Res. 71:1305-1313.
31. Shibata, T., et al. 2002. 15-deoxy-delta 12,14-prostaglandin J2. A prostaglandin D2 metabolite generated during inflammatory processes. J. Biol. Chem. 277:10459-10466.
32. Ragolia, L., et al. 2005. Accelerated glucose intolerance, nephropathy, and atherosclerosis in prostaglandin D2 synthase knock-out mice. J. Biol. Chem. 280:29946-29955.
33. Cipollone, F., et al. 2004. Balance between PGD synthase and PGE synthase is a major determinant of atherosclerotic plaque instability in humans. Arterioscler. Thromb. Vasc. Biol. 24:1259-1265.
34. Inoue, T., et al. 2001. Serum prostaglandin D synthase level after coronary angioplasty may predict occurrence of restenosis. Thromb. Haemost. 85:165-170.
35. Uehara, Y. 2004. PGD(2)/L-PGDS system in hypertension and renal injury [In Japanese]. Nippon Yakurigaku Zasshi. 123:23-33.
36. Zhang, A., Dong, Z., and Yang, T. 2006. Prostaglandin D2 inhibits TGF-beta1-induced epithelial-to-mesenchymal transition in MDCK cells. Am. J. Physiol. Renal Physiol. 291:F1332-F1342.
37. Taniguchi, H., et al. 2007. Prostaglandin D2 protects neonatal mouse brain from hypoxic ischemic injury. J. Neurosci. 27:4303-4312.
38. Yellon, D.M., and Hausenloy, D.J. 2007. Myocardial reperfusion injury. N. Engl. J. Med. 357:1121-1135.
39. Eguchi, N., et al. 1999. Lack of tactile pain (allodynia) in lipocalin-type prostaglandin D synthase-deficient mice. Proc. Natl. Acad. Sci. U. S. A. 96:726-730.
40. Sano, M., et al. 2002. Activation and function of cyclin T-Cdk9 (positive transcription elongation factor-b) in cardiac muscle-cell hypertrophy. Nat. Med. 8:1310-1317.
41. Sano, M., et al. 2007. Intramolecular control of protein stability, subnuclear compartmentalization, and coactivator function of peroxisome proliferator-activated receptor gamma coactivator 1alpha. J. Biol. Chem. 282:25970-25980.
42. Terai, K., et al. 2005. AMP-activated protein kinase protects cardiomyocytes against hypoxic injury through attenuation of endoplasmic reticulum stress. Mol. Cell. Biol. 25:9554-9575.
43. Shinmura, K., et al. 2007. Cardioprotective effects of short-term caloric restriction are mediated by adiponectin via activation of AMP-activated protein kinase. Circulation. 116:2809-2817.